Cite this: Intensive Statin Therapy in Coronary Artery ... MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; NSTEMI = Non-ST elevation acute myocardial infarction ...

Trials of Intensive Statin Therapy in Stable Coronary ... MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; NSTEMI = Non-ST elevation acute myocardial infarction ...

4, 2024 — In addition to lowering your cholesterol, keeping your brain healthy ... activity and is small enough to be packaged within a non-pathogenic virus that can deliver ...

For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical ...

Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner ...

Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ...

So, an elevated LDL cholesterol level is a major risk factor for heart disease and stroke. While lowering LDL cholesterol levels with statin drugs significantly reduces cardiac risk, reducing LDL ...

you may have high cholesterol even if you don’t eat foods that are rich in fat or cholesterol. Low-density lipoprotein (LDL) cholesterol is nicknamed “bad” cholesterol because it can clog ...

The cholesterol-lowering drug has been ... as well as for patients with non-inherited forms of high cholesterol who can’t meet treatment targets with a statin and PCSK9 inhibitor.

Licensed from Novartis, MAR001 is a potential first-in-class antibody. While commonly used statins are effective at lowering LDL cholesterol and triglycerides, MAR001 targets ANGPTL4, a protein highly ...